West Pharmaceutical Services's results for Q3 2026 (ended Sep 30, 2026) come from the company's own earnings release, filed with the SEC on 2026-10-29. Everything below is taken from that filing; quotes are copied exactly. Company outlooks are the company's own.
At a glance
| Item | Value |
|---|---|
| Revenue (GAAP) | $874 million (+8.7% vs a year earlier) |
| Diluted EPS (GAAP) | $3.02 |
| Adjusted per-share figure (company's non-GAAP measure; FFO/AFFO for REITs) | $2.66 |
| Full-year guidance | Raised |
Guidance
Raised 2026 net sales guidance to $3.41–$3.42 billion and adjusted-diluted EPS to $9.38–$9.48; lowered capex range to $215–$220 million.
Why this label: Net sales guide $3.41-3.42B 'up from the previous range of $3.345 billion to $3.380 billion'; adjusted EPS $9.38-9.48 from $8.85-9.05; lower capex is non-core.
| Metric | Period | New | Prior (as stated in the release) |
|---|---|---|---|
| net sales | FY2026 | $3.41–$3.42 billion | $3.345–$3.380 billion |
| organic net sales growth | FY2026 | 11.3%–11.6% | 10%–11% |
| adjusted-diluted EPS | FY2026 | $9.38–$9.48 | $8.85–$9.05 |
| capital spending | FY2026 | $215–$220 million | $250–$275 million |
From the release
Revenue: "Net sales · $ · 874.5 · 100% · $ · 804.6 · 100% · $ · 2,591.7 · 100% · $ · 2,269.1 · 100%"
Earnings per share: "Diluted earnings per share ("EPS") of $3.02 increased 57.3%. • Adjusted-diluted EPS of $2.66 increased 35.7%."
net sales: "Full-year 2026 net sales guidance increased to a range of $3.41 billion to $3.42 billion, up from the previous range of $3.345 billion to $3.380 billion."
organic net sales growth: "Organic net sales growth guidance increased to a range of 11.3% to 11.6%, up from the prior range of 10% to 11%."
adjusted-diluted EPS: "Full-year 2026 adjusted-diluted EPS guidance increased to a range of $9.38 to $9.48, up from the previous range of $8.85 to $9.05."
Quotes are copied from the filing; in table rows, cell borders are shown as “·”.
Key fact: Raised 2026 adjusted EPS guidance to $9.38–$9.48 from $8.85–$9.05.
Source
West Pharmaceutical Services earnings release (SEC filing), accession 0000105770-26-000118, filed 2026-10-29.
Part of the Q3 2026 Guidance Tracker. Educational only, not advice. Free weekly recap every Sunday: yieldterminalpro.com/newsletter.